679435-97-3

Basic information

• Product Name: Acetic acid, (2-aminophenoxy)-, 1,1-dimethylethyl ester
• CAS NO: 679435-97-3
• Molecular Formula: C12H17NO3
• Molecular Weight: 223.272
• Mol File: 679435-97-3.mol

Chemical Properties

• CAS DataBase Reference: Acetic acid, (2-aminophenoxy)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, (2-aminophenoxy)-, 1,1-dimethylethyl ester(679435-97-3)
• EPA Substance Registry System: Acetic acid, (2-aminophenoxy)-, 1,1-dimethylethyl ester(679435-97-3)

Safety Data

• Hazardous Substances Data: 679435-97-3(Hazardous Substances Data)

Upstream product

• 207444-89-1 (2-nitrophenoxy)-acetic acid tert-butyl ester 

Downstream Products

• 207445-07-6 [2-((R)-2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-phenoxy]-acetic acid tert-butyl ester 
• 209258-93-5 [(S)-2-((R)-1-{[(2-tert-Butoxycarbonylmethoxy-phenylcarbamoyl)-methyl]-carbamoyl}-2-phenyl-ethylcarbamoyl)-pyrrolidin-1-yl]-oxo-acetic acid methyl ester 
• 848692-98-8 [2-(N^α-9-fluorenylmethoxycarbonyl-O-benzyl-L-tyrosinamido)phenoxy]acetic acid 
• 1027893-44-2 [(S)-2-((R)-1-{[(2-Carboxymethoxy-phenylcarbamoyl)-methyl]-carbamoyl}-2-phenyl-ethylcarbamoyl)-pyrrolidin-1-yl]-oxo-acetic acid methyl ester 
• 209258-87-7 (S)-2-[(R)-1-(2-tert-Butoxycarbonylmethoxy-phenylcarbamoyl)-2-phenyl-ethylcarbamoyl]-pyrrolidine-1-carboxylic acid benzyl ester 
• 1026163-87-0 ((S)-2-{(R)-1-[2-(2-Carboxymethoxy-phenylcarbamoyl)-ethylcarbamoyl]-2-phenyl-ethylcarbamoyl}-pyrrolidin-1-yl)-oxo-acetic acid methyl ester 
• 207445-10-1 {(S)-2-[(R)-1-(2-tert-Butoxycarbonylmethoxy-phenylcarbamoyl)-2-phenyl-ethylcarbamoyl]-pyrrolidin-1-yl}-oxo-acetic acid methyl ester 

Relevant articles and documents

Quantitative helix handedness bias through a single Hvs.CH3stereochemical differentiation

A novel chiral aromatic δ-amino acid building block was shown to fully induce handedness in quinoline oligoamide foldamers with the possibility of further increasing the bias by combining multiples of these units in the same sequence. Through its incorporation within the helix, both N- and C-termini are still accessible for further functionalisation.

GLYCINE B ANTAGONISTS

The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

CARBOXYALKOXY-SUBSTITUTED ACYL-CARBOXYPHENYL-UREA DERIVATIVES, PRODUCTION METHOD AND USE THEREOF AS MEDICINE

The invention concerns carboxyalkoxy-substituted acyl-carboxyphenyl-urea derivatives of formula (I) wherein the groups are such as defined in the description and their physiologically acceptable salts and their physiologically functional derivatives. The

Syntheses of HIV-protease inhibitors having a peptide moiety which binds to GP120

Some HIV-protease inhibitor derivatives having an N- carbomethoxycarbonyl-prolyl-phenylalanine benzyl ester (CPF) moiety as a binding site to gp120 were designed and synthesized. Almost all the compounds bearing CPF on the phenoxyacetyl group showed protease-inhibitory activity. Compounds 25a and 25b, which have the CPF moiety at the ortho- and meta- positions of the phenoxyacetyl group, respectively, had anti-HIV activity, although the others showed only protease-inhibitory activity. These results suggest that 25b binds to gp120 and inhibits HIV protease.

Synthesis of dipeptide-type human immunodeficiency virus (HIV) protease inhibitors with a binding unit to GP120

Some dipeptide-type human immunodeficiency virus (HIV) protease inhibitors derived from KNI-102, with a N-carbomethoxycarbonylprolyl- phenylalanine benzyl ester (CPF) moiety as a binding site to gp120, were synthesized. Compounds 11a showed 7 - 100 times higher HIV protease- inhibitory activity (11a; IC50 = 0.90 μg/ml, 1.1 μM) than the standard compound 3 or 4 (3; IC50 = 3.7 μg/ml, 7.7 μM, 4; IC50 = 75 μg/ml, 155 μM). Generally, the compounds substituted at the o-position of the phenoxyacetyl group 7a, 11a, 16a and 21a showed several times higher inhibitory activity than 3.